Pituitary-adrenal function following topical triamcinolone acetonide and occlusion.
This study was undertaken to investigate the possible pituitary-adrenal suppressive effects of triamcinolone acetonide under occlusive dressings in six psoriatic patients. Forty-five grams of a cream containing 0.1% triamcinolone acetonide was applied daily to the psoriatic lesions of four patients and covered with an occlusive dressing. Two patients received daily applications of 45 gm of 0.01% triamcinolone acetonide cream and occlusive dressings. The four patients who received the 0.1% triamcinolone acetonide applications showed a marked decrease in the 24-hour urinary 17-hydroxycorticosteroids and no significant response to intravenous metyrapone testing. The two patients who were treated with 0.01% triamcinolone acetonide also showed a significant decrease in 24-hour urinary 17-hydroxycorticosteroids, but a partial response to metyrapone testing. Percutaneous absorption of as little as 1 to 2 mg of triamcinolone acetonide may affect pituitary-adrenal function.
Taylor
K S
KS
Section of Dermatology, Department of Medicine, University of Chicago 60637, USA.
Malkinson
F D
FD
Gak
C
C
D015065:17-Hydroxycorticosteroids / Q000378:metabolism; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009779:Occlusive Dressings; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000502:physiology; D011565:Psoriasis / Q000188:drug therapy; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
D015065:17-Hydroxycorticosteroids; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide